ClinicalTrials.gg
Status unknownNCT03235141Updated Aug 1, 2017

Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

A Phase 1 interventional study of azithromycin eye drops by essex and azithromycin eye drops in Bacterial Conjunctivitis, sponsored by Beijing Tongren Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by Beijing Tongren Hospital · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To compare the pharmacokinetic behavior of azithromycin eye drops in the tear with the original azithromycin eye drops, and evaluate the release behavior of both in the eye.

Read the detailed description

There are 48 patients will divided into group A and group B randomly . subjects of Group A will given the first test drug, elution after the control drug; Subjects of Group B will given the first control drug, elution given to the test drug.

02

Conditions studied

  • Bacterial Conjunctivitis

Keywords

  • Azithromycin eye drops
  • Local Pharmacokinetics
03

In context

Conjunctivitis, Bacterial

40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.

This study's planned enrollment of 56 is below the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.

Browse Conjunctivitis, Bacterial studies →

Lead sponsor

Beijing Tongren Hospital is the lead sponsor of 164 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years old, male or female;
  • in the range of 19 to 28;
  • eyes corrected visual acuity should be ≥ 1.0, intraocular pressure, slit lamp and fundus examination were normal, tear secretion function is normal;
  • Good compliance and voluntarily signed consent.

Exclusion criteria

Exclusion Criteria:

  • Have eye disease or systemic disease;
  • physical examination, laboratory tests, and chest X-ray examination abnormalities and has clinical significance;
  • , anti- and positive;
  • those who used eye drops two weeks before the test and who used any dosage form of azithromycin;
  • known to azithromycin or macrolide-related varieties of allergies or serious adverse reactions;
  • need to wear contact lenses during the test;
  • history of internal surgery or laser surgery history;
  • participated in other drug clinical trials in the past three months;
  • pregnant women and lactating women, or in the growth period without taking effective measures, menstrual period women;
  • mental illness or alcohol, history of drug abuse or inability to collaborate;
  • Any other circumstances that the investigators consider are unfit to participate in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    azithromycin eye drops by essex

    In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg,1 drop,once. In the second cycle(after 14 days elution),give the AzaSite eye drops,2.5ml/25mg,1 drop,once.

    Drug: azithromycin eye drops by essex · Drug: azithromycin eye drops

  • Active comparator
    AzaSite

    In one cycle, give the AzaSite eye drops,2.5ml/25mg,1 drop,once. In the second cycle(after 14 days elution),give the azithromycin eye drops by essex,2.5ml/25mg,1 drop,once.

    Drug: azithromycin eye drops by essex · Drug: azithromycin eye drops

Interventions

  • Drugazithromycin eye drops by essex

    azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),

  • azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc

    Also known as: AzaSite

06

What researchers measure

Primary outcomes

  1. AUC0-t

    The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours,The AUC of the test drug and the control drug was calculated at the average concentration of each point

    Time frame: The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours

Secondary outcomes

  1. Cmax

    The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours,The Cmax of the test drug and the control drug was calculated at the average concentration of each point

    Time frame: The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours

  2. AE

    compared the laboratory test values before and after treatment,according to the study drug use, calculate the number of cases, the number of cases and the incidence of adverse reactions.

    Time frame: from the ICF signed to the end of the trial,through study completion, an average of 1 year

  3. SAE

    Any serious adverse events that occur during the clinical study, whether or not related to the drug should be collected.

    Time frame: from the ICF signed to the end of the trial,through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Beijing Tongren Hospital
    Beijing, Beijing 100005, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03235141
Collaborators
Zhuhai Essex Bio-Pharmaceutical Company Limited, Panacea Technologies
Responsible party
Xiuli Zhao (Director of Phase I Clinical Trial Center, Beijing Tongren Hospital) — Principal investigator
First posted
Aug 1, 2017
Start date
Jul 7, 2017
Primary completion
Oct 30, 2017 (estimated)
Completion
Dec 30, 2017 (estimated)
Last update
Aug 1, 2017

Study contacts

Xiuli Zhao, Doctor
Contact
XL_Zhao_YLJD@163.com
+86-13911901818
Siyang Ni, Doctor
Contact
grandnsy@163.com
+86-18911810275
Xiuli Zhao
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azithromycin

Start the discussion